NDTDI
NDTDI, also known as 9-desmethine-LSD, 9-nor-LSD, or 8,10-seco-LSD, is a psychedelic drug related to lysergic acid diethylamide. It is a tricyclic cyclized tryptamine and partial lysergamide and is a structurally simplified analogue of LSD. The drug is specifically the analogue of LSD in which the carbon atom at position 9 of the ergoline ring system has been removed. It has been reported to produce psychedelic effects similarly to LSD, but with much lower potency. The pharmacology of NDTDI has not been studied. NDTDI was encountered as a novel designer drug by 2016.
File:LSD, 4-desmethine-LSD, and desvinyl-LSD.png|thumb|left|450px|class=skin-invert-image|Structures of LSD, NDTDI , and N-DEAOP-NMT .Interactions
Chemistry
Analogues
s of NDTDI include RU-27849, RU-28306, RU-28251, Bay R 1531, LY-293284, and LY-178210. Other partial/simplified lysergamides include DEIMDHPCA, DEMPDHPCA, and 10,11-seco-LSD, among others. Deletion of the carbon at positions 9 and 10 of the ergoline ring system result in a fully non-rigid tryptamine derivative, N-DEAOP-NMT.History
NDTDI has been sold as a designer drug since 2016 and was first identified by a forensic laboratory in Slovenia in 2017. NDTDI was made illegal in Latvia in March 2017.Legal status
NDTDI is not an explicitly nor implicitly controlled substance in Canada as of 2025.NDTDI is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.